Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

The SCID-hu myeloma model.

Epstein J, Yaccoby S.

Methods Mol Med. 2005;113:183-90.

PMID:
15968103
2.

The SCID-hu mouse: an in vivo model for HIV-1 infection in humans.

Bonyhadi ML, Kaneshima H.

Mol Med Today. 1997 Jun;3(6):246-53. Review.

PMID:
9211415
3.

The SCID-hu mouse: a small animal model for the analysis of human hematolymphoid differentiation and function.

McCune JM.

Bone Marrow Transplant. 1992;9 Suppl 1:74-6. Review. No abstract available.

PMID:
1354528
4.

The use of animal models in multiple myeloma.

Libouban H.

Morphologie. 2015 Jun;99(325):63-72. doi: 10.1016/j.morpho.2015.01.003. Review.

PMID:
25898798
5.

Mouse plasmacytoma: an experimental model of human multiple myeloma.

Gadó K, Silva S, Pálóczi K, Domján G, Falus A.

Haematologica. 2001 Mar;86(3):227-36. Review.

6.

Autoimmunity. Insights provided by the SCID mouse model.

Jorgensen C, Bologna C, Sany J.

Rev Rhum Engl Ed. 1995 Jul-Sep;62(7-8):519-24. Review.

PMID:
8574616
7.

Mouse models of human myeloma.

Mitsiades CS, Anderson KC, Carrasco DR.

Hematol Oncol Clin North Am. 2007 Dec;21(6):1051-69, viii. Review.

PMID:
17996588
8.

The SCID mouse mutant: definition and potential use as a model for immune and hematological disorders.

Leblond V, Autran B, Cesbron JY.

Hematol Cell Ther. 1997 Oct;39(5):213-21. Review.

PMID:
9395894
9.

The SCID mouse: relevance as an animal model system for studying human disease.

Hendrickson EA.

Am J Pathol. 1993 Dec;143(6):1511-22. Review.

10.

[Psoriasis SCID-mouse model].

Pfeffer J, Kaufmann R, Boehncke WH.

Hautarzt. 2006 Jul;57(7):603-9. Review. German.

PMID:
16028077
11.

Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.

Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M, Tagliaferri P.

Curr Cancer Drug Targets. 2012 Sep;12(7):814-22. Review.

12.

The role of the bone marrow microenvironment in multiple myeloma.

De Raeve HR, Vanderkerken K.

Histol Histopathol. 2005 Oct;20(4):1227-50. Review.

PMID:
16136504
13.

Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo.

Thomsen M, Yacoub-Youssef H, Marcheix B.

Tissue Antigens. 2005 Aug;66(2):73-82. Review.

PMID:
16029426
14.

HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model.

Taggart BR, Harrington P, Hollingshead M.

Antiviral Res. 2004 Jul;63(1):1-6. Review.

PMID:
15196814
15.

The SCID-hu xenogeneic transplantation model: complex but telling.

Boehncke WH.

Arch Dermatol Res. 1999 Jul-Aug;291(7-8):367-73. Review.

PMID:
10482004
16.

[Experimental animal models of multiple myeloma].

Miyakawa Y.

Nihon Rinsho. 2007 Dec;65(12):2211-7. Review. Japanese.

PMID:
18069262
18.

Breaking the species barrier: use of SCID mouse-human chimeras for the study of human infectious diseases.

Davis PH, Stanley SL Jr.

Cell Microbiol. 2003 Dec;5(12):849-60. Review.

PMID:
14641171
19.

A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.

Paton-Hough J, Chantry AD, Lawson MA.

Bone. 2015 Aug;77:57-68. doi: 10.1016/j.bone.2015.04.004. Review.

PMID:
25868800
20.

The 5TMM series: a useful in vivo mouse model of human multiple myeloma.

Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K.

Hematol J. 2000;1(5):351-6. Review. No abstract available.

PMID:
11920212

Supplemental Content

Support Center